Financial Performance - The company's revenue for the current period is CNY 229,545,070.92, representing a 2.55% increase compared to CNY 223,832,648.81 in the same period last year[21]. - The net profit attributable to shareholders decreased by 11.66% to CNY 36,923,186.38 from CNY 41,798,412.14 year-on-year[21]. - The gross profit margin declined to 22.02% from 27.20% in the previous year[21]. - The net profit attributable to shareholders after deducting non-operating gains and losses fell by 41.37% to ¥20,903,560.69[34]. - The basic earnings per share fell by 24.62% to CNY 0.54 from CNY 0.72[21]. - The net profit for the current period is CNY 36,971,217.64, reflecting a decrease of 11.62% from CNY 41,831,529.82 in the previous period[55]. - The basic earnings per share for the first half of 2023 was ¥0.52, down from ¥0.70 in the same period of 2022[128]. Assets and Liabilities - Total assets increased by 11.99% to CNY 613,036,311.86, up from CNY 547,418,014.11 at the end of the previous year[22]. - Total liabilities decreased significantly by 65.39% to CNY 58,381,065.43 from CNY 168,702,905.67[22]. - The net assets attributable to shareholders grew by 46.42% to ¥554,841,443.04[34]. - Total liabilities decreased significantly to ¥43,983,483.71 from ¥146,064,382.63, a reduction of about 69.9%[121]. Cash Flow - The net cash flow from operating activities was CNY 72,229,068.18, down 26.76% from CNY 98,614,377.29 in the previous year[23]. - Cash and cash equivalents surged by 759.58% year-over-year, primarily due to funds raised from the company's IPO[50]. - The financing activities generated a net cash flow of CNY 45,325,119.69, a significant improvement from a negative CNY 51,716,802.21 in the previous period, mainly due to funds raised from the IPO[65]. - The net cash inflow from investment activities was $161,086,465.47, compared to $125,022,484.80 in the previous period, representing a 28.9% increase[133]. Research and Development - The company plans to continue expanding its product lines and enhance R&D efforts in konjac-related products[20]. - Research and development expenses increased to CNY 9,579,797.85, representing 4.17% of total revenue, up from 3.87% in the previous period[55]. - The company has invested significantly in R&D for new products and technologies, collaborating with several universities and research institutions to enhance the konjac industry[79]. Market and Industry - The company operates in the food manufacturing industry, regulated by the State Administration for Market Regulation, the Ministry of Commerce, and the National Development and Reform Commission[37]. - China is the leading producer of konjac, with significant advancements in processing technology since the introduction of the first konjac flour machine in 1986, enhancing production efficiency[44]. - The main profit-contributing product for the company is konjac purified micro powder (konjac gum), with sales in China projected to reach 49,400 tons by 2023, reflecting a compound annual growth rate (CAGR) of 14.1% from 2019 to 2023[46]. Corporate Governance and Risks - The actual controllers of the company hold a combined 52.53% voting rights, which poses a risk of undue influence on company decisions[76]. - The company faces risks related to the price volatility of konjac, which significantly impacts production costs[76]. - The company has implemented measures to enhance the supervision functions of independent directors and the supervisory board to protect shareholder interests[76]. Shareholder Information - The largest shareholder, Wu Ping, holds 26.36% of the shares, while the second-largest shareholder, Li Li, holds 14.10%[97]. - The total number of shareholders increased to 2,996 after the public offering[94]. - The company completed a public offering of 15.525 million shares, increasing total share capital from 58.229 million to 73.754 million shares[94]. Compliance and Regulations - The company adheres to high standards and strict requirements for production and product quality, aligning with national food safety regulations and industry development directions[43]. - The "Food Safety Law of the People's Republic of China" was enacted in 2021 to ensure food safety and public health, establishing a legal framework for food production and safety[38]. - The company’s products meet national legal requirements for food safety, creating a favorable market environment for further development[43]. Environmental and Social Responsibility - The company actively participates in public welfare donation activities to fulfill its social responsibility[74]. - The company has established an environmental monitoring plan to ensure that waste gas, wastewater, and noise meet discharge standards[75]. Financial Reporting and Accounting Policies - There were no changes in accounting policies or estimates compared to the previous year's financial statements[149]. - The financial statements comply with the requirements of the enterprise accounting standards, accurately reflecting the company's financial position and operating results[157]. - The company’s financial statements reflect a seasonal characteristic in its operations, particularly in the procurement of konjac raw materials[150].

证券代码：839273 证券简称：一致魔芋 公告编号：2023-072 湖北一致魔芋生物科技股份有限公司 关于接待机构投资者调研情况的公告 本公司及董事会全体成员保证公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担个别及连带责任。 湖北一致魔芋生物科技股份有限公司（以下简称"公司"）于 2023 年 4 月 28 日（星期五）下午 15:00-16:30 在湖北长阳经济开发区长阳大道 438 号公司 二楼会议室举办了线上机构投资者调研活动，现将主要情况公告如下： 一、调研情况 调研时间： 2023 年 4 月 28 日（星期五）下午 15:00-16:30 调研地点：湖北长阳经济开发区长阳大道 438 号公司二楼会议室 调研形式：线上调研 调研机构：开源证券、上投摩根基金、西部利得基金、兴华基金、兴证资 产、中山证券、工银国际、建信信托、大家资产、递归基金、纯达资产、东北 证券等 上市公司接待人员：公司董事长、总经理吴平女士、公司董事会秘书唐华 林先生、证券事务代表董琴女士 二、机构投资者调研主要内容 公司董事会秘书唐华林先生在线上介绍了公司基本情况，并同时就投资者 关心 ...

Financial Performance - Net profit attributable to shareholders decreased by 19.30% to ¥14,808,575.31 year-on-year[11] - Operating income rose by 11.72% to ¥109,205,034.80 compared to the same period last year[11] - Total revenue for Q1 2023 reached ¥109,205,034.80, an increase of 11.9% compared to ¥97,745,382.51 in Q1 2022[46] - Net profit for Q1 2023 was ¥14,811,650.45, a decrease of 19.0% from ¥18,356,649.78 in Q1 2022[48] - The company's operating profit decreased to ¥18,126,307.42 from ¥20,964,441.44, representing a decline of approximately 13.8% year-over-year[51] - Net profit for the period was ¥15,102,441.64, down from ¥18,219,719.89, indicating a decrease of about 17.4% compared to the previous year[51] - Total revenue from sales of goods and services was ¥115,200,842.68, slightly down from ¥116,204,423.78 in the same period last year[53] Assets and Liabilities - Total assets increased by 29.30% to ¥707,800,073.17 compared to the end of last year[11] - The company's total assets as of March 31, 2023, amount to RMB 707.8 million, an increase from RMB 547.4 million as of December 31, 2022[39] - Total liabilities decreased to ¥135,705,083.79 in Q1 2023 from ¥146,064,382.63 in Q1 2022, a reduction of 7.8%[44] - The company's current liabilities decreased from RMB 138.9 million to RMB 124.3 million between December 31, 2022, and March 31, 2023[40] - The company has pledged assets totaling RMB 34.9 million, representing 4.93% of total assets, primarily for loan guarantees[34] Cash Flow - Cash flow from operating activities decreased by 57.12% to ¥5,242,859.59 year-on-year[12] - The net cash flow from operating activities was ¥5,242,859.59, a significant decrease of 57.0% from ¥12,225,708.77 in the prior year[55] - Cash and cash equivalents at the end of the period increased to ¥163,890,453.95, compared to ¥55,991,916.98 at the end of the same period last year[55] - The ending balance of cash and cash equivalents was $163,631,704.01, up from $55,021,506.85[57] - Cash received from tax refunds was $5,839,442.23, an increase from $4,781,240.28[57] Shareholder Information - The number of ordinary shareholders increased to 3,332 by the end of the reporting period[17] - The company reported a total of 56,144,000 shares held by major shareholders, representing 75.86% of total shares[21] - The largest shareholder, Wu Ping, holds 19,440,000 shares, accounting for 26.36% of total shares[21] Investments and Future Plans - The company plans to continue expanding its market presence and product development in the upcoming quarters[7] - The company plans to use up to RMB 150 million of idle raised funds for cash management, investing in high-security and high-liquidity financial products[27] - The company plans to use up to RMB 400 million of its idle funds for cash management, with a maximum single investment period of 12 months[28] Legal and Compliance - There were no significant litigation or arbitration matters during the reporting period[25] - The company has not provided any external guarantees or loans during the reporting period[24] - The company has not experienced any freezing, seizure, or pledge of assets during the reporting period[24] - The company has not implemented any employee incentive plans or share repurchase programs[24] - The company disclosed all promised matters in a timely manner as per the annual report[24] Research and Development - Research and development expenses for Q1 2023 were ¥3,990,185.00, slightly up from ¥3,760,150.39 in Q1 2022[47] - Research and development expenses were ¥3,319,899.33, slightly down from ¥3,442,349.61, indicating a focus on cost management in R&D[51]

证券代码：839273 证券简称：一致魔芋 公告编号：2023-055 本公司及董事会全体成员保证公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担个别及连带责任。 一、说明会类型 本次业绩说明会将采用网络方式召开，投资者可登陆全景网"投资者关系 互动平台"（http://ir.p5w.net）参与本次业绩说明会。 湖北一致魔芋生物科技股份有限公司（以下简称"公司"）于 2023 年 3 月 23 日在北京证券交易所信息披露平台（www.bse.cn）披露了《2022 年年度报告》 （公告编号：2023-030）及《2022 年年度报告摘要》（公告编号：2023-029）， 为方便广大投资者更深入了解公司 2022 年年度经营业绩的具体情况，加强与投 资者的互动交流，公司拟召开 2022 年年度报告业绩说明会。 二、说明会召开的时间、地点 （一）会议召开时间：2023 年 4 月 7 日（星期五）15:00-17：00。 （二）会议召开地点 湖北一致魔芋生物科技股份有限公司 2022 年年度报告业绩说明会预告公告 三、参会人员 四、投资者参加方式 本次说明会采用网络方式召开 ...

Financial Performance - The company's operating revenue for 2022 was ¥447.35 million, a decrease of 10.66% compared to ¥500.75 million in 2021[27]. - The net profit attributable to shareholders for 2022 was ¥65.30 million, an increase of 10.02% from ¥59.35 million in 2021[27]. - The gross profit margin improved to 24.58% in 2022, up from 21.05% in 2021[27]. - Total assets increased by 30.16% to ¥547.42 million in 2022, compared to ¥420.57 million in 2021[29]. - Total liabilities rose by 57.38% to ¥168.70 million in 2022, up from ¥107.19 million in 2021[29]. - The company's cash flow from operating activities was negative at ¥88.72 million in 2022, a decline of 169.05% from ¥128.49 million in 2021[31]. - The accounts receivable turnover ratio was 9.22 in 2022, down from 10.53 in 2021[32]. - The inventory turnover ratio decreased to 1.49 in 2022, compared to 2.41 in 2021[32]. - The company reported a net profit of ¥65,341,535.79 in 2022, reflecting a 10.25% increase from ¥59,265,250.99 in 2021[60]. - The company's equity attributable to shareholders grew by 20.82% to CNY 378,949,336.31, with a net asset value per share of CNY 6.51, up 20.78%[51]. Revenue Sources and Market Dependence - The company reported a significant increase in revenue, with the main business income from konjac hydrophilic colloid (konjac powder) accounting for a high proportion of total revenue[12]. - The proportion of overseas customers in the main business income was 44.27%, 43.47%, and 39.78% over the past three years, indicating a substantial reliance on international markets[12]. - The proportion of overseas customer revenue has decreased from 44.27% to 40.29% over the past three years, indicating a risk of declining international sales due to external factors[136]. - The revenue from konjac hydrophilic colloid (konjac powder) accounted for a significant portion of the company's main business income, posing a risk if market preferences change or new substitute products emerge[130]. Research and Development - The company has established strong R&D partnerships with several universities and research institutions to enhance product development and technological innovation[13]. - The company emphasizes R&D, collaborating with several universities and research institutions to enhance product development and innovation[46]. - The company has established 72 patents, including 24 invention patents, 37 utility model patents, and 11 design patents[47]. - Research and development (R&D) expenses amounted to ¥16,334,233.78, accounting for 3.65% of operating income, compared to 3.37% in the previous period[92]. - The company has a total of 30 R&D personnel, representing 6.73% of the total workforce, slightly down from 6.82%[94]. Inventory and Supply Chain Management - The company reported a significant increase in inventory levels, with the book value of inventory reaching 211.76 million yuan, indicating potential risks related to inventory turnover and cash flow[12]. - The company's inventory increased significantly by 189.16% to CNY 335,817,008.78, indicating a strategic buildup of raw materials[56]. - The company's inventory value at year-end was 211.76 million, 116.13 million, and 335.82 million over the past three years, highlighting potential risks related to inventory turnover and cash flow[138]. - The company has a high supplier concentration risk, with the top five suppliers accounting for 58.10%, 67.65%, and 59.42% of procurement amounts over the past three years[12]. - The total procurement amount from major suppliers reached ¥330,017,877.68, representing 59.42% of total procurement[75]. Corporate Governance and Risk Management - The company has maintained a favorable corporate governance structure to protect shareholder interests, despite the actual controllers holding 66.16% of voting rights[12]. - The company faces risks related to raw material price fluctuations, as the cost of konjac and its initial processing products constitutes a significant portion of production costs[12]. - The company enjoys a 15% corporate income tax rate as a high-tech enterprise, but there is a risk of losing this status due to policy changes or internal conditions, which could negatively impact profitability[129]. - The company is committed to improving its internal control systems and management levels to enhance operational efficiency and governance[122]. - The company will implement measures to manage foreign exchange risks, as a significant portion of its revenue comes from exports denominated in USD and EUR[126]. Market Trends and Opportunities - The market demand for konjac flour is projected to reach 49,400 tons by 2023, with a compound annual growth rate of 14.1% from 2019 to 2023[54]. - The konjac food industry is experiencing steady growth, with the market expected to expand due to increasing consumer demand for healthy food options[111]. - The Japanese konjac market shows significant potential, with per capita consumption at 621 yen in 2020, indicating a large growth opportunity for China to reach similar levels[112]. - The company identifies three trends in the konjac industry: a shift towards deep processing, increasing market concentration, and growing consumer acceptance of konjac products[114]. - The rural revitalization strategy is expected to boost the konjac industry, with government support enhancing the economic viability of konjac cultivation[115]. Social Responsibility and Environmental Commitment - The company actively participates in social responsibility by supporting the konjac industry and providing equipment and technical support to cooperatives, contributing to rural development[108]. - The company has implemented environmental monitoring plans for waste gas, wastewater, and noise, ensuring all emissions meet standards[109]. - The company has been recognized as an advanced private enterprise in the "Thousand Enterprises Helping Thousand Villages" poverty alleviation initiative[107]. Future Plans and Strategic Initiatives - The company plans to expand its production capacity and product line, ensuring sustainable growth through the completion of construction and equipment installation for konjac gum and konjac snack food production lines within the year[121]. - The company aims to enhance its product development capabilities by increasing third-party collaborations to research the properties and health functions of konjac gum and dietary fiber[119]. - The company is focusing on expanding its market share through innovative konjac products and enhanced marketing strategies[97]. - The company will deepen cooperation with konjac cooperatives and processing plants to stabilize raw material supply and improve supply chain management[118]. - The company recognizes the limited public awareness of konjac and aims to enhance market education and acceptance of konjac products[116].

Revenue and Profit - The company reported a revenue of ¥447,353,301.41 for the year 2022, a decrease of 10.66% compared to ¥500,750,248.73 in the previous year[4] - Net profit attributable to shareholders increased by 9.91% to ¥65,233,619.73, up from ¥59,352,699.10 in the previous year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses rose by 13.34% to ¥57,908,131.03, compared to ¥51,093,578.52 last year[4] - Basic earnings per share increased by 9.90% to ¥1.12, up from ¥1.02 in the previous year[4] Assets and Equity - Total assets at the end of the reporting period reached ¥547,821,284.75, reflecting a year-on-year growth of 30.26%[5] - Shareholders' equity attributable to the company increased by 20.80% to ¥378,882,152.83, compared to ¥313,648,533.10 at the beginning of the period[5] - The company's inventory of raw materials significantly increased due to enhanced procurement efforts, impacting the total assets positively[5] Operational Challenges and Market Dynamics - The decline in revenue was attributed to logistics disruptions caused by frequent COVID-19 outbreaks, affecting sales deliveries[6] - The company experienced an increase in the shipment volume of konjac powder products, although the sales price per unit decreased[6] - The gross profit margin improved due to a decrease in raw material procurement prices, which fell more than the decline in product sales prices[6]

证券简称： 一致魔芋 证券代码： 839273 长阳经济开发区长阳大道 438 号 湖北一致魔芋生物科技股份有限公司 HUBEI YIZHI KONJAC BIOTECHNOLOGY CO.,LTD. 湖北一致魔芋生物科技股份有限公司招股说明书 本次股票发行后拟在北京证券交易所上市，该市场具有较高的投资风险。北京证 券交易所主要服务创新型中小企业，上市公司具有经营风险高、业绩不稳定、退市风 险高等特点，投资者面临较大的市场风险。投资者应充分了解北京证券交易所市场的 投资风险及本公司所披露的风险因素，审慎作出投资决定。 保荐机构（主承销商） 深圳市南山区粤海街道海珠社区滨海大道 3165 号五矿金融大厦 2401 湖北一致魔芋生物科技股份有限公司 招股说明书 中国证监会和北京证券交易所对本次发行所作的任何决定或意见，均不表 明其对注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不 表明其对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或 者保证。任何与之相反的声明均属虚假不实陈述。 根据《证券法》的规定，股票依法发行后，发行人经营与收益的变化，由 发行人自行负责；投资者自主判断发行人的投 ...